DaVita (NYSE:DVA) Releases FY 2026 Earnings Guidance

DaVita (NYSE:DVA) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 14.100-15.200 for the period, compared to the consensus estimate of 14.130. The company issued revenue guidance of -.

DaVita Stock Performance

Shares of DVA stock traded up $2.90 during trading hours on Tuesday, hitting $156.98. 1,992,106 shares of the company were exchanged, compared to its average volume of 984,548. The stock has a market capitalization of $10.49 billion, a price-to-earnings ratio of 15.84, a P/E/G ratio of 0.53 and a beta of 0.84. DaVita has a one year low of $101.00 and a one year high of $159.42. The business’s 50-day simple moving average is $151.18 and its two-hundred day simple moving average is $131.51.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.54. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The firm had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.36 billion. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, analysts anticipate that DaVita will post 14.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DVA has been the topic of several research reports. Truist Financial set a $158.00 price target on DaVita in a research report on Thursday, February 5th. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Barclays increased their target price on shares of DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 3rd. UBS Group lifted their price target on shares of DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. Finally, Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. One investment analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $155.80.

Hedge Funds Weigh In On DaVita

Several hedge funds and other institutional investors have recently modified their holdings of DVA. Caitlin John LLC acquired a new stake in shares of DaVita in the 4th quarter worth about $34,000. Canada Pension Plan Investment Board acquired a new position in DaVita during the 2nd quarter valued at about $43,000. Kestra Advisory Services LLC bought a new position in DaVita in the 4th quarter worth about $45,000. iSAM Funds UK Ltd bought a new position in DaVita in the 3rd quarter worth about $46,000. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of DaVita in the fourth quarter valued at approximately $50,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.